Festen D A M, de Weerd A W, van den Bossche R A S, Joosten K, Hoeve H, Hokken-Koelega A C S
Dutch Growth Foundation, Westzeedijk 106, 3016 AH Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 2006 Dec;91(12):4911-5. doi: 10.1210/jc.2006-0765. Epub 2006 Sep 26.
Recently, several cases of sudden death in GH-treated and non-GH-treated, mainly young Prader-Willi syndrome (PWS), patients were reported. GH treatment in PWS results in a remarkable growth response and an improvement of body composition and muscle strength. Data concerning effects on respiratory parameters, are however, limited.
The objective of the study was to evaluate effects of GH on respiratory parameters in prepubertal PWS children.
Polysomnography was performed before GH in 53 children and repeated after 6 months of GH treatment in 35 of them.
Fifty-three prepubertal PWS children (30 boys), with median (interquartile range) age of 5.4 (2.1-7.2) yr and body mass index of +1.0 sd score (-0.1-1.7).
Intervention included treatment with GH 1 mg/m2.d.
Apnea hypopnea index (AHI) was 5.1 per hour (2.8-8.7) (normal 0-1 per hour). Of these, 2.8 per hour (1.5-5.4) were central apneas and the rest mainly hypopneas. Duration of apneas was 15.0 sec (13.0-28.0). AHI did not correlate with age and body mass index, but central apneas decreased with age (r = -0.34, P = 0.01). During 6 months of GH treatment, AHI did not significantly change from 4.8 (2.6-7.9) at baseline to 4.0 (2.7-6.2; P = 0.36). One patient died unexpectedly during a mild upper respiratory tract infection, although he had a nearly normal polysomnography.
PWS children have a high AHI, mainly due to central apneas. Six months of GH treatment does not aggravate the sleep-related breathing disorders in young PWS children. Our study also shows that monitoring during upper respiratory tract infection in PWS children should be considered.
最近,有报道称生长激素(GH)治疗组和非GH治疗组(主要是年轻的普拉德-威利综合征(PWS)患者)出现了几例猝死病例。PWS患者接受GH治疗后会有显著的生长反应,身体成分和肌肉力量也会得到改善。然而,关于对呼吸参数影响的数据有限。
本研究的目的是评估GH对青春期前PWS儿童呼吸参数的影响。
对53名儿童在接受GH治疗前进行了多导睡眠图检查,其中35名儿童在接受GH治疗6个月后重复进行了检查。
53名青春期前PWS儿童(30名男孩),中位(四分位间距)年龄为5.4(2.1 - 7.2)岁,体重指数为+1.0标准差评分(-0.1 - 1.7)。
干预措施包括每天使用1mg/m²的GH进行治疗。
呼吸暂停低通气指数(AHI)为每小时5.1次(2.8 - 8.7)(正常为每小时0 - 1次)。其中,每小时2.8次(1.5 - 5.4)为中枢性呼吸暂停,其余主要为低通气。呼吸暂停持续时间为每次15.0秒(13.0 - 28.0)。AHI与年龄和体重指数无关,但中枢性呼吸暂停随年龄增加而减少(r = -0.34,P = 0.01)。在6个月的GH治疗期间,AHI从基线时的4.8(2.6 - 7.9)变化至4.0(2.7 - 6.2;P = 0.36),无显著变化。一名患者在轻度上呼吸道感染期间意外死亡,尽管他的多导睡眠图检查结果几乎正常。
PWS儿童的AHI较高,主要是由于中枢性呼吸暂停。6个月的GH治疗不会加重年轻PWS儿童与睡眠相关的呼吸障碍。我们的研究还表明,应考虑对PWS儿童上呼吸道感染期间进行监测。